Stryker Corporation
SYK
$276.97
+0.57%
Stryker Corporation designs, manufactures, and markets medical equipment, instruments, consumable supplies, and implantable devices, spanning reconstructive orthopaedics (hip and knee replacements, extremities), MedSurg (endoscopy systems, operating room equipment, hospital beds and gurneys), and neurovascular/robotics products, with roughly one-fourth of revenue generated outside the United States. The company is one of the three largest competitors in reconstructive orthopedic implants and holds a leadership position in operating room equipment, giving it a scale and cross-selling advantage that smaller med-tech peers cannot easily replicate. The current investor narrative has turned decidedly negative: despite a solid Q2 2026 print with revenue of $6.589 billion (+9.42% YoY) and EPS of $3.32, the stock has fallen roughly 25% over the past year and about 12% in the last month alone, dramatically underperforming a rising SPY. Management is leaning on M&A to refresh the portfolio — the May 2026 completion of the Amplitude Vascular Systems acquisition adds next-generation intravascular lithotripsy technology to the peripheral vascular franchise — but the market is clearly debating whether tariff and input-cost pressure, procedure-mix headwinds, and a rich historical multiple justify the recent de-rating.…
SYK
Stryker Corporation
$276.97
Related headlines
Investment Opinion: Should I buy SYK Today?
The synthesized recommendation is a Hold with a bullish bias, reflecting the disconnect between solid fundamentals and negative price momentum. The core thesis is that Stryker's 9.4% revenue growth, expanding margins, and forward PE of 16.5x make it fundamentally undervalued, but the persistent downtrend and lack of a technical bottom warrant caution until a catalyst emerges. The analyst consensus rating of 'buy' (mean 1.68) and average target of $367.80 imply 33.5% upside, anchoring the bullish view.
Supporting evidence includes: 1) Revenue growth of 9.42% YoY in Q2 2026, with both MedSurg and Orthopaedics contributing; 2) Gross margin expansion to 68.27% from 62.27%, and net margin improvement to 19.37% from 14.68%; 3) Free cash flow of $4.702 billion, providing a 3.5% FCF yield and covering the 0.96% dividend; 4) Forward PE of 16.47x, a steep discount to the historical 38x-63x band and the 20-25x peer average. The implied upside to the average analyst target is 33.5%, and even the low target of $298 offers 8.2% upside.
The biggest risks that could invalidate the thesis are: 1) A breakdown below the 52-week low of $267, which could trigger momentum selling; 2) Further margin compression from tariffs or input costs, reversing the Q2 gains; 3) A miss on Q3 earnings or guidance cut. The rating would upgrade to Buy if the stock reclaims $300 and margins hold above 65%, or downgrade to Sell if revenue growth decelerates below 5% or gross margin falls below 60%. Relative to its history and peers, the stock appears undervalued on a forward earnings basis, but the market is pricing in significant uncertainty.
Sign up to view all
SYK 12-Month Price Forecast
Stryker presents a compelling value opportunity on a forward earnings basis, with a forward PE of 16.47x that is less than half its historical average and a 33.5% upside to analyst targets. However, the stock is in a severe downtrend, down 24.8% over one year and underperforming SPY by 39.84 percentage points, indicating that the market is pricing in significant risks. The key tension is whether the recent margin expansion (gross margin up to 68.27%) is sustainable; if it is, the stock is deeply undervalued, but if tariffs and input costs erode margins, the discount is justified. I would upgrade to bullish if the stock reclaims $300 and Q3 earnings show margin stability, and downgrade to bearish if it breaks below $267 or revenue growth decelerates below 5%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Stryker Corporation's 12-month outlook, with a consensus price target around $366.15 and implied upside of +32.2% versus the current price.
Average Target
$366.15
0 analysts
Implied Upside
+32.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$298 - $465
Analyst target range
Coverage is deep and institutional, with 25 analysts following Stryker and a consensus recommendation of "buy" (recommendation mean of 1.68, where 1.0 is a strong buy and 3.0 is a hold). The average price target of $367.80 implies roughly 33.5% upside from the current price of $275.43, a spread that is unusually wide and signals that the sell-side believes the recent decline is overdone. Consensus 2027 EPS estimates of $23.06 (range $22.63-$23.94) and revenue estimates of $37.79 billion (range $37.25-$38.90 billion) underpin that bullishness, and the fact that the average target sits 33.5% above spot while the stock trades near its 52-week low is a classic contrarian setup — either analysts are early, or the market is mispricing a high-quality compounder.
The target range runs from a low of $298.00 to a high of $465.00, a $167 spread that represents roughly 61% of the current share price and signals meaningful disagreement about the path forward. The high target of $465 implies a full recovery to prior highs and would require multiple expansion back toward the 25x-30x forward PE range plus successful integration of recent M&A and a resolution of margin headwinds; the low target of $298 implies only modest upside and prices in continued multiple compression and slower procedure volumes. Recent institutional ratings show a clear pattern of stability rather than capitulation: Stifel reiterated Buy on September 30, 2026, Citigroup reiterated Buy on September 10, Wells Fargo reiterated Overweight on September 9, and JP Morgan, Piper Sandler, and RBC Capital all reiterated bullish ratings on July 31 — the only notable downgrade was Wolfe Research moving to Peer Perform from Outperform on August 13, 2026. The absence of broad downgrades despite a 25% drawdown suggests the sell-side views this as a valuation reset within an intact long-term growth story, though the wide target spread and the stock's failure to respond to reiterated Buy ratings indicate the market is waiting for tangible evidence of a fundamental trough before re-engaging.
Bulls vs Bears: SYK Investment Factors
The bear case currently has stronger momentum evidence, with the stock in a well-established downtrend and no technical signs of a bottom. However, the bull case is supported by solid fundamental performance—9.4% revenue growth, expanding margins, and a forward PE of 16.5x that is less than half the historical average. The single most important tension is whether the recent margin expansion (gross margin up to 68.27%) is durable or whether tariff and input-cost pressures will reverse it; if margins hold, the stock is deeply undervalued, but if they compress, the discount is justified. Analyst consensus strongly favors the bulls with a $367.80 average target, but the market's refusal to rally on reiterated Buy ratings suggests skepticism until tangible evidence of a fundamental trough emerges.
Bullish
- Revenue growth remains solid at 9.4% YoY: Q2 2026 revenue of $6.589 billion grew 9.42% year-over-year, with both MedSurg ($3.625 billion) and Orthopaedics ($2.964 billion) contributing meaningfully. This demonstrates that the fundamental demand for Stryker's products remains intact despite the stock's 24.8% one-year decline.
- Forward PE of 16.5x is deeply discounted: The forward PE of 16.47x is well below the historical PE band of 38x-63x and the typical 20-25x range for large-cap med-tech peers. This suggests the market is pricing in a severe earnings deterioration that has not materialized in the actual results.
- Analyst consensus implies 33.5% upside: With 25 analysts covering the stock and a consensus 'buy' rating (mean 1.68), the average price target of $367.80 represents 33.5% upside from the current $275.43. The low target of $298 still implies 8.2% upside, indicating that even the most cautious analysts see limited downside.
- Profitability is expanding, not contracting: Q2 2026 gross margin expanded to 68.27% from 62.27% a year earlier, and net margin jumped to 19.37% from 14.68%. Operating margin of 25.18% and EBITDA margin of 23.74% are well above med-tech peer averages, showing strong operational execution.
Bearish
- Severe and accelerating downtrend: The stock is down 24.83% over one year, 15.65% over three months, and 11.77% over one month, underperforming SPY by 39.84, 18.99, and 12.36 percentage points respectively. The September 8 gap down of 8.8% from $303.13 to $276.43 shows intense selling pressure with no bullish divergence.
- Valuation still not cheap on all metrics: While forward PE is low, the EV/EBITDA of 23.23x and PEG ratio of 5.16 are elevated, and the price-to-free-cash-flow of 26.6x leaves little room for error. The trailing PE of 41.40x is distorted by a low EPS base, but the market may be correctly pricing a growth slowdown.
- Margin headwinds from tariffs and input costs: Q1 2026 net margin collapsed to 12.38% with $148 million in interest expense, highlighting earnings volatility. Management faces tariff and input-cost pressures that could erode the recent margin expansion, and the Q2 rebound may not be sustainable.
- Analyst target dispersion signals uncertainty: The target range from $298 to $465 is a $167 spread (61% of the current price), indicating significant disagreement about the company's path. The stock has failed to respond to reiterated Buy ratings from Stifel, Citigroup, and Wells Fargo, suggesting the market is waiting for tangible evidence of a trough.
SYK Technical Analysis
Stryker is in a well-established downtrend, with the 1-year price change at -24.83% and the current price of $275.43 sitting at just 6.7% above the 52-week low of $267.00 and 29.8% below the 52-week high of $392.55. Measured against the 52-week range, the stock is trading at roughly 6.7% of its range from the bottom — a positioning that typically signals either deep value or a falling knife, and given the persistent negative momentum, the burden of proof is on the bulls. The stock has also underperformed SPY by a staggering 39.84 percentage points over the past year, confirming this is a stock-specific de-rating rather than a market-wide pullback.
Recent momentum is unambiguously negative and accelerating to the downside: the 1-month change is -11.77% versus SPY's +0.59% (relative strength of -12.36), and the 3-month change is -15.65% versus SPY's +3.34% (relative strength of -18.99). The most violent leg lower occurred in early September 2026, when the stock gapped from $303.13 on September 4 to $276.43 on September 8 — a single-session decline of roughly 8.8% — and it has since failed to reclaim even $285, chopping between $269.75 and $284.76. This 1-month weakness is consistent with, not divergent from, the 1-year downtrend, meaning there is no bullish divergence to trade against; the 6-month change of -16.92% and YTD change of -20.89% confirm a sustained, multi-quarter distribution phase rather than a temporary pullback.
Key technical levels are clearly defined: support sits at the 52-week low of $267.00, with the recent intraday lows of $269.75 (September 24) and $270.01 (September 10) forming a tight base just above it, while resistance is anchored at the 52-week high of $392.55, with intermediate resistance around $285-$300 where the stock repeatedly failed in September. A breakdown below $267 would open the door to a fresh leg lower and likely trigger momentum-driven selling, whereas a reclaim of $300 would be the first meaningful sign of trend repair. Volatility is a critical consideration here: beta of 0.768 means the stock is roughly 23% less volatile than SPY on a day-to-day basis, which is unusually defensive for a name in a 25% drawdown — this suggests the decline is driven by fundamental re-rating rather than high-beta market sensitivity, and the max drawdown of -31.59% underscores how painful the move has been for holders despite the low beta.
Beta
0.78
0.78x market volatility
Max Drawdown
-31.6%
Largest decline past year
52-Week Range
$267-$393
Price range past year
Annual Return
-26.2%
Cumulative gain past year
| Period | SYK Return | S&P 500 |
|---|---|---|
| 1m | +0.2% | +1.0% |
| 3m | -16.0% | +2.5% |
| 6m | -18.3% | +13.9% |
| 1y | -26.2% | +15.0% |
| ytd | -20.5% | +13.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SYK Fundamental Analysis
Stryker's revenue trajectory remains healthy even as the stock price collapses: Q2 2026 revenue of $6.589 billion grew 9.42% year-over-year versus Q2 2025's $6.022 billion, and the sequential progression from Q1 2026's $6.020 billion shows steady execution. The segment mix is balanced, with MedSurg contributing $3.625 billion and Orthopaedics $2.964 billion, meaning the company is not overly dependent on any single franchise. However, the multi-quarter trend shows some lumpiness — Q4 2025 revenue of $7.171 billion was the high-water mark, and the Q1 2026 dip to $6.020 billion reflects normal seasonality rather than deterioration. The key takeaway is that the fundamental growth engine is intact at roughly 9% YoY, which makes the 25% stock decline look like a multiple compression story rather than a growth breakdown.
Profitability is robust and, importantly, improving: Q2 2026 net income was $1.276 billion on a 19.37% net margin, up sharply from Q2 2025's $884 million and 14.68% net margin, while gross margin expanded to 68.27% from 62.27% a year earlier. Operating income of $1.659 billion produced a 25.18% operating margin, and EBITDA of $1.564 billion equates to a 23.74% EBITDA margin — all comfortably above the mid-teens to low-20s margins typical of large-cap med-tech peers. The one blemish is Q1 2026, when net income of $745 million and a 12.38% net margin reflected $148 million of interest expense and a heavier tax load, but the Q2 rebound confirms that was a timing issue, not a structural margin problem. With trailing gross margin at 63.96% and net margin at 12.92% on a TTM basis, Stryker remains a high-quality, cash-generative compounder.
Balance sheet and cash flow metrics are solid but not pristine: debt-to-equity of 0.73 and a current ratio of 1.89 indicate manageable leverage and adequate liquidity, while trailing free cash flow of $4.702 billion against a $134.3 billion market cap implies an FCF yield of roughly 3.5%. ROE of 14.48% and ROA of 8.16% are respectable for a capital-intensive device manufacturer, and Q2 2026 operating cash flow of $1.261 billion comfortably covered $202 million of capex and $337 million of dividends. The company is generating enough internal cash to fund both its dividend (payout ratio of 39.56%, yield of 0.96%) and bolt-on M&A like the $437 million Amplitude Vascular deal, though the Q1 2026 debt repayment of $1.0 billion and the 2025 acquisitions show management is willing to use the balance sheet aggressively. The main watch item is the elevated price-to-free-cash-flow ratio of 26.6x on the pcf_ratio metric, which leaves less room for error if growth slows.
Quarterly Revenue
$6.6B
2026-06
Revenue YoY Growth
+9.4%
YoY Comparison
Gross Margin
68.3%
Latest Quarter
Free Cash Flow
$4.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SYK Overvalued?
Because Stryker is solidly profitable — Q2 2026 net income of $1.276 billion and positive TTM earnings — the PE ratio is the appropriate primary metric. The trailing PE of 41.40x versus a forward PE of 16.47x is a striking gap that implies the market expects a massive earnings inflection; however, this gap is largely an artifact of the trailing figure being distorted by a very low reported EPS base (the key metrics show EPS of just $0.024, likely reflecting a data quirk or one-time charge), while the forward PE of 16.47x is anchored on consensus 2027 EPS of roughly $23.06. On the forward metric, the stock looks genuinely cheap for a med-tech leader growing revenue at 9%+.
Relative to the broader medical devices sector, Stryker's forward PE of 16.47x screens at a discount to the typical 20-25x range for large-cap orthopedics and MedSurg peers, while its PS ratio of 5.35x and EV/Sales of 4.52x are in line to slightly below where high-quality device names usually trade. The EV/EBITDA of 23.23x is the one metric that looks full, and the PEG ratio of 5.16 is elevated, suggesting the market is not yet pricing in the earnings recovery implied by the forward PE. The premium/discount debate hinges on whether the recent margin expansion (gross margin up to 68.27% in Q2 2026) is durable — if it is, the forward multiple is too low; if tariffs and input costs bite, the discount is deserved.
Historically, Stryker has traded in a PE band of roughly 38x-63x over the past several years (historical ratios show quarterly PE readings of 41.4x, 42.1x, 39.8x, 41.1x, 42.6x, 54.4x, and 62.9x), so the current trailing PE of 41.40x sits near the low end of its own historical range. The PS ratio tells a similar story: the current 5.35x compares to historical quarterly PS readings that ranged from 18.3x to 25.1x, though those figures appear to use a different share-count basis and are not directly comparable. What matters is the directional signal: the stock is being valued at the cheapest levels in years on both earnings and sales, which either represents a compelling value opportunity or reflects the market's judgment that the growth and margin trajectory is about to deteriorate — the forward PE of 16.47x versus the historical 38x-63x band strongly suggests the market is pricing in a worst-case scenario.
PE
41.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 38x~46x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are moderate but rising. Debt-to-equity of 0.73 and a current ratio of 1.89 indicate manageable leverage, but Q1 2026 saw $148 million in interest expense and a net margin drop to 12.38%, highlighting earnings volatility. The price-to-free-cash-flow ratio of 26.6x leaves little room for error if growth slows, and the company's aggressive M&A strategy (e.g., the $437 million Amplitude Vascular deal) could strain the balance sheet if integrations underperform. Additionally, roughly one-fourth of revenue comes from outside the U.S., exposing Stryker to currency fluctuations and geopolitical risks.
Market and competitive risks are significant given the stock's 24.8% one-year decline and 39.84 percentage point underperformance versus SPY. The forward PE of 16.47x is a discount to peers, but the EV/EBITDA of 23.23x and PEG of 5.16 suggest the market is pricing in slower growth. Beta of 0.768 indicates lower volatility than the market, but the stock has still suffered a max drawdown of -31.59%, showing that the de-rating is company-specific. Competitive threats from Boston Scientific and others in the med-tech space, along with potential regulatory headwinds, could further pressure the multiple.
The worst-case scenario would involve a breakdown below the 52-week low of $267, triggered by a miss on Q3 earnings, further margin compression from tariffs, or a failed M&A integration. In this scenario, the stock could fall to the analyst low target of $298—but that is above the current price, so the true downside may be to the 52-week low of $267, representing a 3.1% decline from current levels. However, if fundamentals deteriorate sharply, a drop to $250 (roughly 9.2% below current) is possible, implying a total loss of about 9% from the current price of $275.43. The max drawdown of -31.59% from the peak already illustrates the pain investors have endured.
FAQ
The key risks include: 1) Financial risk: Q1 2026 net margin dropped to 12.38% with $148 million in interest expense, showing earnings volatility; 2) Competitive risk: Boston Scientific and other med-tech peers are vying for market share, and Stryker's 24.8% one-year decline suggests company-specific issues; 3) Macro risk: tariff and input-cost pressures could erode the recent gross margin expansion to 68.27%; 4) Technical risk: a breakdown below the 52-week low of $267 could trigger momentum selling, with the max drawdown already at -31.59%. The most severe risk is a sustained margin compression that would justify the current low multiple.
The 12-month forecast includes three scenarios: bull case (30% probability) targeting $367.80-$465.00, driven by margin expansion and multiple recovery; base case (50% probability) targeting $298.00-$367.80, assuming steady growth and gradual multiple expansion; bear case (20% probability) targeting $267.00-$298.00, triggered by earnings misses or margin compression. The base case is most likely, with a target around the analyst average of $367.80, implying 33.5% upside. The key assumption is that revenue growth remains in the 8-10% range and gross margin holds above 65%.
SYK appears undervalued on a forward earnings basis, with a forward PE of 16.47x compared to its historical range of 38x-63x and the 20-25x typical for large-cap med-tech peers. The PS ratio of 5.35x and EV/Sales of 4.52x are also below historical levels, though the EV/EBITDA of 23.23x and PEG of 5.16 suggest the market is pricing in slower growth. The trailing PE of 41.40x is distorted by a low EPS base, but the forward multiple implies the market expects a significant earnings recovery. If Stryker delivers on consensus 2027 EPS of $23.06, the stock is cheap; if growth slows, the discount may be deserved.
From a risk/reward perspective, SYK offers a favorable setup for long-term investors, with a forward PE of 16.47x and a 33.5% upside to the analyst average target of $367.80. The company is growing revenue at 9.42% YoY with expanding margins, yet the stock trades just 6.7% above its 52-week low, pricing in significant pessimism. However, the biggest downside risk is a breakdown below $267, which could trigger further selling and a drop to $250 or lower. For investors with a 2-3 year horizon who can withstand near-term volatility, the risk/reward is attractive, but short-term traders should wait for a technical bottom or a reclaim of $300 before entering.
SYK is best suited for long-term investors with a minimum holding period of 2-3 years, given its strong fundamentals, dividend yield of 0.96%, and low beta of 0.768. The stock is in a downtrend with negative momentum, making it a poor candidate for short-term trading unless a clear technical reversal occurs. The company's consistent revenue growth, expanding margins, and strategic M&A support a long-term compounding thesis, but near-term volatility may persist until the market recognizes the value. Short-term traders should wait for a reclaim of $300 or a confirmed bottom before entering.